Customers who struggle to afford the $1,000-plus list price for weight-loss drugs Zepbound and Wegovy can buy now and pay ...

Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity ...

Novo Nordisk has acquired the global rights to China-based United Laboratories’ triple-agonist weight-loss and diabetes drug ...

Glucagon-like peptide-1 agonists, a class of medications known as GLP-1s, have grown in popularity, initially for the ...

Fact checked by Nick Blackmer While GLP-1 drugs like Ozempic and Wegovy can lead to rapid and significant weight loss, they ...

It was only a matter of time until the GLP-1 receptor agonist drugs like Ozempic and Wegovy were superseded, and now it looks ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

Amy Schumer’s experience with Mounjaro has been vastly different from when she tried an alternative weight-loss medication ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.

Everyone is talking about different diets that can help you lose weight, but do we really know what works and what doesn't?

Glucagon-like peptide-1 (GLP-1) and Gastric inhibitory polypeptide (GIP) while Ozempic (Semaglutide) only targets GLP-1.

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.